AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01101503
Drug: Intensive multifactorial group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~1. For blood glucose control, target HbA1c \>=5.5%and \<=6.0%,fasting blood glucose \>=5.0 mmol/L and \<=6.0 mmol/L, postprandial 2 hour glucose \>= 6.0 mmol/L and \<= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \< =1.9 mmol/L, triglyceride \< =1.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>=120/70 mmHg and \<= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin.
Trial: NCT01101503
Drug: conventional multifactorial therapy group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~1. For blood glucose control, target HbA1c \>6.5%and \<=7.0%,fasting blood glucose \>6.0 mmol/L and \<=7.0 mmol/L, postprandial 2 hour glucose \> 7.8 mmol/L and \<= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \> 1.9 mmol/L and \< =2.5 mmol/L, triglyceride \> 1.5 mmol/L and \< = 2.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>130/80 mmHg and \<= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin.
Trial: NCT04312698
Drug: D013, D326, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337
Trial: NCT04312698
Drug: placebo of D013, D326, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013
Trial: NCT04312698
Drug: D013, placebo of D326, placebo of D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337
Trial: NCT04188184
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
Trial: NCT01972893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I.
Trial: NCT00590590
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semi solid, twice weekly for 4 months
Trial: NCT00625092
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Post-operative day 1 and day 2, 600mg/m\^2 intraperitoneal (IP) held for 23 hours
Trial: NCT00625092
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 0 200 mg/m\^2 intraperitoneal held for 2 hours
Trial: NCT01863511
Drug: loop diuretic
RxNorm normalized name: Loop diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03847987
Drug: RO7017773 Phase II Tablet Unflavored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.
Trial: NCT03847987
Drug: RO7017773 Phase II Tablet Sweetened/Flavored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
Trial: NCT00356278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered in the same manner as the active drugs.
Trial: NCT00647556
Drug: tretinoin 0.05% emollient cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied topically once daily in the evening
Trial: NCT00616863
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04342663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
Trial: NCT00404963
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00404963
Drug: GSK376501
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03365466
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH 5000u IH qd
Trial: NCT04316585
Drug: GSK2982772
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 will be available as MR tablet at a unit dose strength of 480 mg.
Trial: NCT04316585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 matching placebo tablets will be administered via the oral route.
Trial: NCT00541931
Drug: Dietary Supplement: LifePak Nano
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use
Trial: NCT00959231
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02814565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine HCl extended release placebo-matching capsules
Trial: NCT02113735
Drug: H.P. Acthar® Gel (repository corticotropin injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02113735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01340209
Drug: Placebo Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium placebo once daily delivered with Respimat inhaler
Trial: NCT03690765
Drug: Duphaston® (Dydrogesterone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.
Trial: NCT03690765
Drug: Duphaston® (Dydrogesterone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.
Trial: NCT01165047
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
Trial: NCT01875562
Drug: Qishe Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill, 3.75 g, twice per day, four weeks
Trial: NCT02805166
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00284791
Drug: Fluoxetine (drug)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03904329
Drug: Oral Anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets of anti coagulations either warfare or NOACs
Trial: NCT02163018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of increasing doses of placebo
Trial: NCT03520036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo QD, oral, 16 weeks
Trial: NCT01227421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, (2 tablets) twice daily with food for 5 days
Trial: NCT02288338
Drug: 1 (Ezetrol®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 1 (Lipitor®, Ezetrol®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 2 (Ezetrol®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 2(Lipitor®, Ezetrol®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 2 (Lipitor®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 4 (Lipitor®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 4(Lipitor®, Ezetrol®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 4 (Ezetrol®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 5 (Ezetrol®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 5 (Lipitor®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 5 (Lipitor®, Ezetrol®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Trial: NCT02288338
Drug: 6(Lipitor®, Ezetrol®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Trial: NCT00000559
Drug: estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01507272
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
Trial: NCT00312910
Drug: Probiotics-Bio-plus
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02706873
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsule or Tablet; Oral
Trial: NCT02706873
Drug: Placebo to Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule or Tablet; Oral
Trial: NCT01898065
Drug: 18-F-MISO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET scan with the 18 Fluoro Misonidazole
Trial: NCT01241214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered twice daily.
Trial: NCT02982161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Dosing frequency: four times daily, Mode of administration: oral
Trial: NCT00672984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
Trial: NCT00382993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: NCT00382993
Drug: Combination Product (sumatriptan succinate/naproxen sodium)
RxNorm normalized name: naproxen sodium / sumatriptan Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
Trial: NCT01045980
Drug: Usual care and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (not bioimpedance guided volume management) and Placebo
Trial: NCT01061450
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg once a day
Trial: NCT01247103
Drug: AZD4316
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
Trial: NCT01247103
Drug: AZD4316
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
Trial: NCT01061450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill once a day
Trial: NCT00785330
Drug: standard GVHD prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
Trial: NCT01441752
Drug: TCM
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
Trial: NCT01441752
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
Trial: NCT00796562
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient will receive Cy by IV once a day for 2 days.
Trial: NCT01308554
Drug: Placebo: sterile normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral TAP block using 20 ml of normal sterile saline per block.
Trial: NCT00302965
Drug: Frozen Plasma
RxNorm normalized name: Fresh frozen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00278278
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01787357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
Trial: NCT02942563
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME.
Trial: NCT04375943
Drug: Antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
Trial: NCT01118598
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
Trial: NCT00789386
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
Trial: NCT01660243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2capsules) once daily for 8 weeks
Trial: NCT03682978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet.
Trial: NCT00391222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of placebo every 2 weeks and oral placebo daily
Trial: NCT02387580
Drug: OZ439 Prototype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02387580
Drug: OZ439 Prototype 3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00795821
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
Trial: NCT00795821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 3 tablets QD for 10 weeks
Trial: NCT03602287
Drug: Lignocaine 2% Injection 20Ml Vial (Product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack
Trial: NCT03602287
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack
Trial: NCT03353857
Drug: Norethindrone/ Noriday
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Period 1, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 1, In Period 2, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 15 In Period 3, 0.35 mg single dose administered as 1x0.35 mg tablet at Study Day 26
Trial: NCT03353857
Drug: Drospirenone, Ethinylestradiol/ Yasmin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Period 1, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 1, In Period 2, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 15, In Period 3, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 26,
Trial: NCT02380976
Drug: combination drug: DW330SR, DW1030
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00461045
Drug: MRZ 0.5 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
Trial: NCT00014768
Drug: leucine
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02768701
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
Trial: NCT04537689
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablet up to 15mg per week
Trial: NCT04176835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02249910
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
Trial: NCT02303626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01548651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
Trial: NCT04511728
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial Induction dose of HSK3486 is 0.4 mg/kg. The initial maintenance dose of HSK3486 is 0.8 mg/kg/h